Dr. Akshay Budhraja

Associate Director

11 Years of Experience

Medicine Specialist, Pulmonologist

MBBS, MD, Fellowship, MBA

Reg. No.:86400, Delhi Medical Council

English, Hindi

Consultation Fee ₹ 1200

Book an Appointment Contact with Doctor

Expert Help When You Need It – Plan in 60 Minutes

Name*

Mobile Number*

Is the above number on WhatsApp? *

Yes

Query

Dr. Akshay Budhraja is a well-known pulmonologist with more than 11 years of experience.
His expertise covers bronchial asthma, COPD, pneumonia, respiratory failure, ILD, pulmonary hypertension, sleep disorders, smoking cessation, tuberculosis, sarcoidosis, and lung cancer.
Dr. Budhraja is a respiratory and sleep medicine expert with clinical proficiency in treating critically ill patients and a wide range of respiratory conditions.
He successfully performed over 3500 Bronchoscopies, 500 EBUS, and 150 Thoracostomies.
He completed his MBBS from Barkatullah University and MD in Tuberculosis & Respiratory Diseases/Medicine from People's College of Medical Sciences & Research Centre.
He is also associated with many medical societies, including the Indian Chest Society, India, Indian Medical Association (IMA), the Delhi Medical Council, India (DMC), and the Haryana Medical Council, India(HMC)
Dr. Akshay was the principal investigator of 6 International Drug Trials and 3 Ongoing International Drug Trials for COVID-19.
He also did various learning programs at the Royal College of Physicians, London.

Expert Help When You Need It – Plan in 60 Minutes

Name*

Mobile Number*

Is the above number on WhatsApp? *

Yes

Query

MBBS, Barkatullah University, Bhopal, 2013
MD, (Respiratory Medicine), People's College of Medical Sciences & Research Centre, 2016
Fellowship Respiratory & Sleep Medicine, Medanta-The Medicity, Gurgaon, 2018
MBA, (Health Care Administration/Management), University of Virginia Darden School of Business, 2021

Attending Consultant, Venkateshwar Hospitals, 2019
Senior Resident, (Pulmonary Medicine) All India Institute of Medical Sciences, Bhopal, 2017
Senior Resident, LN Medical College Bhopal,2016

DFV890: a new oral NLRP3 inhibitor—tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial